• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

理解多发性骨髓瘤的缺氧微环境:小鼠模型的治疗意义和贡献。

Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models.

机构信息

Department of Genetics and Molecular Biology, Medical School of Xi'an Jiaotong University, Xi'an, China.

出版信息

Dis Model Mech. 2012 Nov;5(6):763-71. doi: 10.1242/dmm.008961.

DOI:10.1242/dmm.008961
PMID:23115205
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3484859/
Abstract

Multiple myeloma (MM) is the second most common hematological malignancy and is characterized by the clonal expansion of plasma cells in the bone marrow. Recently, hypoxia has received increased interest in the context of MM, in both basic and translational research. In this review, we describe the discovery of the hypoxic niche in MM and how it can be targeted therapeutically. We also discuss mouse models that closely mimic human MM, highlighting those that allow preclinical research into new therapies that exploit the hypoxic niche in MM.

摘要

多发性骨髓瘤(MM)是第二大常见血液系统恶性肿瘤,其特征是骨髓中浆细胞的克隆性扩张。最近,缺氧在 MM 的基础和转化研究中受到了越来越多的关注。在这篇综述中,我们描述了 MM 中缺氧小生境的发现以及如何对其进行治疗性靶向。我们还讨论了与人类 MM 非常相似的小鼠模型,突出了那些允许对利用 MM 缺氧小生境的新疗法进行临床前研究的模型。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f713/3484859/dbfbdccc1276/DMM008961F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f713/3484859/02d2f6153190/DMM008961F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f713/3484859/dbfbdccc1276/DMM008961F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f713/3484859/02d2f6153190/DMM008961F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f713/3484859/dbfbdccc1276/DMM008961F2.jpg

相似文献

1
Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models.理解多发性骨髓瘤的缺氧微环境:小鼠模型的治疗意义和贡献。
Dis Model Mech. 2012 Nov;5(6):763-71. doi: 10.1242/dmm.008961.
2
Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells.缺氧诱导因子-2 是多发性骨髓瘤浆细胞中异常 CXCL12 表达的新型调节因子。
Haematologica. 2010 May;95(5):776-84. doi: 10.3324/haematol.2009.015628. Epub 2009 Dec 16.
3
The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma.缺氧、HIF-1 和 HIF-2 在多发性骨髓瘤中的新作用。
Leukemia. 2011 Oct;25(10):1533-42. doi: 10.1038/leu.2011.122. Epub 2011 Jun 3.
4
Hypoxia-inducible hexokinase-2 enhances anti-apoptotic function via activating autophagy in multiple myeloma.缺氧诱导的己糖激酶 2 通过激活自噬增强多发性骨髓瘤的抗凋亡功能。
Cancer Sci. 2020 Nov;111(11):4088-4101. doi: 10.1111/cas.14614. Epub 2020 Sep 8.
5
Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression.缺氧骨髓微环境在5T2MM小鼠骨髓瘤肿瘤进展中的作用。
Haematologica. 2005 Jun;90(6):810-7.
6
Hypoxia-inducible microRNA-210 regulates the DIMT1-IRF4 oncogenic axis in multiple myeloma.缺氧诱导的微小RNA-210调控多发性骨髓瘤中的DIMT1-IRF4致癌轴。
Cancer Sci. 2017 Apr;108(4):641-652. doi: 10.1111/cas.13183. Epub 2017 Apr 20.
7
Influence of metformin on HIF-1 pathway in multiple myeloma.二甲双胍对多发性骨髓瘤中HIF-1通路的影响。
Pharmacol Rep. 2020 Oct;72(5):1407-1417. doi: 10.1007/s43440-020-00142-x. Epub 2020 Jul 27.
8
Impact of hypoxia on the pathogenesis and therapy resistance in multiple myeloma.缺氧对多发性骨髓瘤发病机制和治疗耐药性的影响。
Cancer Sci. 2021 Oct;112(10):3995-4004. doi: 10.1111/cas.15087. Epub 2021 Aug 9.
9
Morphogens and growth factor signalling in the myeloma bone-lining niche.骨髓瘤骨衬里龛中的形态发生素和生长因子信号传导。
Cell Mol Life Sci. 2021 May;78(9):4085-4093. doi: 10.1007/s00018-021-03767-0. Epub 2021 Feb 11.
10
The pathogenesis of the bone disease of multiple myeloma.多发性骨髓瘤骨病的发病机制。
Bone. 2008 Jun;42(6):1007-13. doi: 10.1016/j.bone.2008.01.027. Epub 2008 Feb 21.

引用本文的文献

1
Therapeutic Potential of Venetoclax and Selinexor in Targeting Hypoxia-Induced Vulnerabilities in Multiple Myeloma.维奈托克和塞利尼索针对多发性骨髓瘤中缺氧诱导的脆弱性的治疗潜力
Cancer Rep (Hoboken). 2025 Jun;8(6):e70249. doi: 10.1002/cnr2.70249.
2
Tunneling nanotubes between bone marrow stromal cells support transmitophagy and resistance to apoptosis in myeloma.骨髓基质细胞间的隧道纳米管支持骨髓瘤中的线粒体自噬及抗凋亡作用。
Blood Cancer J. 2025 Jan 9;15(1):3. doi: 10.1038/s41408-025-01210-2.
3
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins.

本文引用的文献

1
Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy.在多发性骨髓瘤的基因工程小鼠模型中,药物反应可预测临床疗效。
Blood. 2012 Jul 12;120(2):376-85. doi: 10.1182/blood-2012-02-412783. Epub 2012 Mar 26.
2
Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features.缺氧通过获得上皮间质转化样特征促进多发性骨髓瘤的扩散。
Blood. 2012 Jun 14;119(24):5782-94. doi: 10.1182/blood-2011-09-380410. Epub 2012 Mar 6.
3
Animal models: Towards a myeloma mouse.
仅是冰山一角:针对细胞膜蛋白的多发性骨髓瘤新型治疗方法。
Nat Rev Clin Oncol. 2024 Aug;21(8):590-609. doi: 10.1038/s41571-024-00913-y. Epub 2024 Jul 3.
4
Acidification of intracellular pH in MM tumor cells overcomes resistance to hypoxia-mediated apoptosis and .多发性骨髓瘤(MM)肿瘤细胞内pH值的酸化克服了对缺氧介导的细胞凋亡的抗性。
Front Oncol. 2023 Nov 3;13:1268421. doi: 10.3389/fonc.2023.1268421. eCollection 2023.
5
Metabolic crosstalk between stromal and malignant cells in the bone marrow niche.骨髓微环境中基质细胞与恶性细胞之间的代谢串扰。
Bone Rep. 2023 Feb 27;18:101669. doi: 10.1016/j.bonr.2023.101669. eCollection 2023 Jun.
6
Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche.多发性骨髓瘤中的耐药性:骨髓微环境中的“士兵”与“武器”
Front Oncol. 2022 Sep 21;12:973836. doi: 10.3389/fonc.2022.973836. eCollection 2022.
7
Prognostic Value of Association of Copy Number Alterations and Cell-Surface Expression Markers in Newly Diagnosed Multiple Myeloma Patients.新诊断多发性骨髓瘤患者拷贝数改变与细胞表面表达标志物联合的预后价值。
Int J Mol Sci. 2022 Jul 7;23(14):7530. doi: 10.3390/ijms23147530.
8
Diversity in the bone marrow niche: Classic and novel strategies to uncover niche composition.骨髓龛的多样性:揭示龛组成的经典和新策略。
Br J Haematol. 2022 Dec;199(5):647-664. doi: 10.1111/bjh.18355. Epub 2022 Jul 15.
9
Autophagy and the Bone Marrow Microenvironment: A Review of Protective Factors in the Development and Maintenance of Multiple Myeloma.自噬与骨髓微环境:多发性骨髓瘤发病和维持中的保护因子研究进展。
Front Immunol. 2022 May 19;13:889954. doi: 10.3389/fimmu.2022.889954. eCollection 2022.
10
RNA-Sequencing-Based Transcriptomic Score with Prognostic and Theranostic Values in Multiple Myeloma.基于RNA测序的转录组评分在多发性骨髓瘤中的预后及诊疗价值
J Pers Med. 2021 Sep 30;11(10):988. doi: 10.3390/jpm11100988.
动物模型:迈向骨髓瘤小鼠模型
Nature. 2011 Dec 14;480(7377):S38-9. doi: 10.1038/480S38a.
4
Targeting hypoxic tumour cells to overcome metastasis.针对缺氧肿瘤细胞以克服转移。
BMC Cancer. 2011 Nov 30;11:504. doi: 10.1186/1471-2407-11-504.
5
Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104.在小鼠和人类白血病模型中表现出明显的缺氧现象:缺氧激活前药 PR-104 具有高疗效。
PLoS One. 2011;6(8):e23108. doi: 10.1371/journal.pone.0023108. Epub 2011 Aug 11.
6
Investigation on tumor hypoxia in resectable primary prostate cancer as demonstrated by 18F-FAZA PET/CT utilizing multimodality fusion techniques.利用多模态融合技术的 18F-FAZA PET/CT 对可切除原发性前列腺癌肿瘤乏氧的研究。
Eur J Nucl Med Mol Imaging. 2011 Oct;38(10):1816-23. doi: 10.1007/s00259-011-1876-z. Epub 2011 Jul 16.
7
The microenvironment and molecular biology of the multiple myeloma tumor.多发性骨髓瘤肿瘤的微环境和分子生物学。
Adv Cancer Res. 2011;110:19-42. doi: 10.1016/B978-0-12-386469-7.00002-5.
8
The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma.缺氧、HIF-1 和 HIF-2 在多发性骨髓瘤中的新作用。
Leukemia. 2011 Oct;25(10):1533-42. doi: 10.1038/leu.2011.122. Epub 2011 Jun 3.
9
Targeting hypoxia in cancer therapy.针对癌症治疗中的缺氧。
Nat Rev Cancer. 2011 Jun;11(6):393-410. doi: 10.1038/nrc3064.
10
Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1α, CAIX, LDH-5, GLUT-1, MCT1 and MCT4.与缺氧相关的代谢标志物;染色模式及缺氧诱导因子-1α、碳酸酐酶 IX、乳酸脱氢酶 5、葡萄糖转运蛋白 1、单羧酸转运蛋白 1 和单羧酸转运蛋白 4 的共定位。
BMC Cancer. 2011 May 12;11:167. doi: 10.1186/1471-2407-11-167.